Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90

Blood Adv. 2023 Nov 14;7(21):6665-6667. doi: 10.1182/bloodadvances.2023010944.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Hodgkin Disease* / diagnosis
  • Hodgkin Disease* / drug therapy
  • Humans
  • Lymphoma, Non-Hodgkin*
  • Prognosis